Clinical trials: Immune Deficiencies
Dementia, Dementia Frontotemporal
Care Planning for a Loved One With Dementia: Knowledge, Preparing for Decisions, and Emotions
The overall objective of this study is to compare knowledge, decisional conflict, preferences, and caregiver burden over time caregivers of Alzheimer's Disease and Related Dementias (ADRD) patients by comparing the effectiveness…
- Conditions
- Dementia, Dementia Frontotemporal, Dementia Alzheimers, Dementia, Mild
- Trial name
- NCT05165186
- Testing
- Video Intervention Arm
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Immunoglobulin Light-chain Amyloidosis
Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis
The purpose of this clinical trial is to evaluate whether specific probiotic can reduce gastrointestinal symptoms and improves therapeutic response, on a background of Bortezomib+dexamethasone or Bortezomib+dexamethasone combined…
- Trial name
- NCT05776940
- Testing
- Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab, Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab
- Volunteers
- 116 people
- Sponsor
- Air Force Military Medical University, China
AL Amyloidosis
Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
The goal of this clinical trial is to learn if Equecabtagene Autoleucel(Eque-cel), a Chimeric Antigen Receptor T-cell (CAR-T) therapy, works to treat severe Light Chain (AL) Amyloidosis in newly diagnosed adults with Mayo Stage…
- Trial name
- NCT07055724
- Testing
- Eque-cel CAR-T Therapy
- Volunteers
- 17 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Primary Amyloidosis
A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
The treatment with oral melphalan and prednisone has been recommended as standard treatment of AL amyloidosis but the results are rather disappointing.
- Trial name
- LEOMEX (NCT00883623)
- Testing
- Lenalidomide
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Amyloidosis, Immunoglobulin Light-chain
Cardiac Amyloidosis Registry Study
This registry is a observational, multi-center study designed to collect data and analyze it retrospectively on patients with cardiac amyloidosis who have been evaluated and treated at major amyloid centers across the US and…
- Trial name
- CARS (NCT05174338)
- Testing
- Registry
- Where
- 23 sites in United States, Canada
- Volunteers
- 5,000 people
- Sponsor
- Cedars-Sinai Medical Center
Multiple Myeloma
Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography
[18F]Florbetaben PET/CT imaging will noninvasively assess amyloid deposition in systemic amyloidosis.
- Trial name
- PET (NCT03779815)
- Testing
- [18F]Florbetaben
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Ulsan University Hospital
Chronic Myeloproliferative Disorders, Leukemia
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005804
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Amyloidosis
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
The purpose of this study is to determine the safety and activity of the combination of lenalidomide with intermediate dose dexamethasone and cyclophosphamide in patients with primary systemic (AL ) amyloidosis.
- Trial name
- NCT00981708
- Testing
- Lenalidomide, Dexamethasone and Cyclophosphamide
- Where
- Greece
- Volunteers
- 37 people
- Sponsor
- University of Athens
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have advanced cancer and liver…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
- Trial name
- NCT00025415
- Testing
- imatinib mesylate, pharmacological study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
REM Sleep Behavior Disorder
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
This is a phase 2 study to assess the ability of adalimumab as compared to placebo to reduce or prevent progression of synuclein-related neurodegeneration in persons with idiopathic REM Sleep Behavior Disorder (RBD).
- Trial name
- PRISMS (NCT06996652)
- Testing
- Adalimumab
- Where
- 18 sites in United States, Canada
- Volunteers
- 108 people
- Sponsor
- Yale University
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Primary Systemic Amyloidosis
Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
The purpose of this study is to evaluate the efficacy of Enbrel in patients with primary systemic Amyloidosis.
- Trial name
- NCT00224393
- Testing
- Enbrel
- Volunteers
- 60 people
- Sponsor
- The Cleveland Clinic
Relapsed/Refractory Multiple Myeloma (RRMM), Light-Chain Amyloidosis
Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis.
- Trial name
- NCT07874334
- Testing
- GPRC5D CART
- Where
- Israel
- Volunteers
- 160 people
- Sponsor
- Hadassah Medical Organization
Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
Background: Anakinra is a drug used to treat people with certain diseases that affect their immune systems. Sometimes anakinra can cause proteins under the skin to clump together.
- Trial name
- NCT06974877
- Testing
- 124I AT-01
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Amyloidosis, Basal Cell Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and…
- Conditions
- Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma
- Trial name
- NCT07285044
- Testing
- Cancer Therapeutic Procedure, Questionnaire Administration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
AL Amyloidosis
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who…
- Trial name
- PRONTO (NCT02632786)
- Testing
- NEOD001
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Prothena Biosciences Ltd.
Multiple Myeloma, Amyloidosis
A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
Patients with multiple myeloma (a type of blood cancer affecting the white blood cells) or amyloidosis (abnormal buildup of a protein called amyloid in the body) are often given treatment with the drugs lenalidomide or…
- Trial name
- NCT03959358
- Testing
- Lenalidomide, Pomalidomide
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Amyloid Light-chain Amyloidosis
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
This research study is for people who have newly diagnosed with AL (light chain) amyloidosis and have not yet received any treatment for this condition.
- Trial name
- NCT07524634
- Testing
- BCMA bispecific
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Case Comprehensive Cancer Center
Iron-Deficiency Anemia
Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy
Multicentre, randomised, controlled, 2-arm open-label prospective pilot study to evaluate efficacy and safety of ferric carboxymaltose (FCM) in treatment of anaemia in subjects with multiple myeloma (MM) initiating chemotherapy.
- Trial name
- AOC-MM (NCT01100879)
- Testing
- Ferric carboxymaltose
- Where
- 2 sites in France, Greece
- Volunteers
- 3 people
- Sponsor
- Vifor Pharma
AL Amyloidosis
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
This is a phase 1/2 open label study of melphalan flufenamide (melflufen) in combination with dexamethasone for participants with Al amyloidosis following at least one prior line of therapy.
- Trial name
- NCT04115956
- Testing
- Melphalan-Flufenamide (Melflufen), Dexamethasone
- Where
- 9 sites in United States, Czechia and 7 more
- Volunteers
- 6 people
- Sponsor
- Oncopeptides AB